Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infinity Gears Up For Duvelisib Filing, But Differentiation Still A Challenge

Executive Summary

Duvelisib is on track for parallel filings for CLL and iNHL in 2016, but the company still has work to do in differentiating the PI3 kinase inhibitor, which it says could come through additional studies beyond pivotal trials.


Related Content

Infinity Gets More Than A Cash Boost With AbbVie Tie-Up
In A Competitive New Cancer Field, Infinity Looks For A Place To Play


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts